Skip to main content
. 2017 May 26;265(5):946–953. doi: 10.1097/SLA.0000000000001793

TABLE 4.

Unadjusted Factors Associated with Overall Survival in EGC and AGC

RFS OS
Variable HR 95% CI P HR 95% CI P
EGC
WHO histology and grade
 PD (vs WMD) 0.82 0.53 to 1.26 0.357 0.73 0.54 to 0.98 0.036
 SRC (vs WMD) 0.26 0.14 to 0.49 <0.001 0.30 0.20 to 0.45 <0.001
SRC (vs non-SRC) 0.28 0.15 to 0.52 <0.001 0.33 0.22 to 0.48 <0.001
Age at diagnosis 1.03 1.01 to 1.04 0.002 1.09 1.07 to 1.10 <0.001
Female sex 0.55 0.36 to 0.84 0.005 0.45 0.34 to 0.61 <0.001
AJCC stage II (vs stage I) 7.22 4.59 to 11.37 <0.001 3.08 2.03 to 4.69 <0.001
Submucosal invasion 2.02 1.40 to 2.92 <0.001 1.65 1.30 to 2.09 <0.001
Lymph node metastasis 6.15 4.27 to 8.88 <0.001 2.43 1.80 to 3.28 <0.001
Location*
 Middle (vs upper) 1.60 0.67 to 3.80 0.289 0.99 0.64 to 1.53 0.952
 Lower (vs upper) 2.10 0.92 to 4.81 0.080 0.93 0.61 to 1.42 0.735
AGC
WHO histology and grade
 PD (vs WMD) 1.40 1.23 to 1.60 <0.001 1.31 1.16 to 1.49 <0.001
 SRC (vs WMD) 1.42 1.19 to 1.69 <0.001 1.36 1.15 to 1.60 <0.001
SRC (vs non-SRC) 1.15 0.99 to 1.34 0.066 1.15 1.00 to 1.33 0.050
Age at diagnosis 1.00 1.00 to 1.01 0.650 1.02 1.02 to 1.03 <0.001
Female sex 1.13 1.00 to 1.27 0.051 1.05 0.93 to 1.17 0.452
AJCC stage
 Stage II (vs stage I) 3.72 2.50 to 5.53 <0.001 2.14 1.61 to 2.83 <0.001
 Stage III (vs stage I) 14.20 9.75 to 20.68 <0.001 7.02 5.42 to 9.09 <0.001
Tumor stage
 T3 (vs T2) 2.28 1.80 to 2.89 <0.001 1.90 1.55 to 2.33 <0.001
 T4 (vs T2) 5.75 4.68 to 7.06 <0.001 4.24 3.57 to 5.05 <0.001
Node stage
 N1 (vs N0) 2.29 1.82 to 2.90 <0.001 1.69 1.38 to 2.07 <0.001
 N2 (vs N0) 3.91 3.16 to 4.84 <0.001 2.64 2.19 to 3.18 <0.001
 N3 (vs N0) 8.82 7.29 to 10.67 <0.001 6.31 5.39 to 7.40 <0.001
Location
 Middle (vs upper) 0.96 0.81 to 1.15 0.684 0.97 0.82 to 1.14 0.683
 Lower (vs upper) 1.05 0.89 to 1.24 0.566 1.05 0.90 to 1.23 0.532
 Whole (vs upper) 2.98 1.53 to 5.83 0.001 5.35 3.11 to 9.20 <0.001

AGC indicates advanced gastric cancer; CI, confidence interval, EGC, early gastric cancer; HR, hazard ratio; PD, poorly differentiated; SRC, signet ring cell carcinoma; WMD, well-to-moderately differentiated.

*Only two EGC patients had ‘whole stomach’ cancers and were therefore excluded from analysis.